




RealRate

PHARMACEUTICAL 2019

Amneal Pharmaceuticals Inc.
Rank 229 of 363





RealRate

PHARMACEUTICAL 2019

Amneal Pharmaceuticals Inc.
Rank 229 of 363



The relative strengths and weaknesses of Amneal Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Amneal Pharmaceuticals Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Amneal Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 182% points.

The company's Economic Capital Ratio, given in the ranking table, is 37%, being 0.20% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	1,286,644
Cost of Goods Sold	946,588
Intangible Assets	2,081,195
Liabilities, Current	553,850
Liabilities, Non-Current	2,902,523
Other Assets	440,751
Other Compr. Net Income	177,966
Other Expenses	332,332
Other Liabilities	0
Other Net Income	-160,749
Other Revenues	1,662,991
Property and Equipment	544,146
Research and Development	194,190
Selling, General and Administrative Expense	230,435

Output Variable	Value in 1000 USD
Assets	4,352,736
Liabilities	3,456,373
Expenses	1,703,545
Revenues	1,662,991
Stockholders Equity	896,363
Net Income	-201,303
Comprehensive Net Income	-112,320
Economic Capital Ratio	37%